Work

Translational inhalable extracellular vesicle‐based mRNA therapy for the treatment of lung cancer

Year: 2025

Type: editorial

Abstract: Translational inhalable extracellular vesicle-based mRNA therapy for the treatment of lung cancerLung cancer remains the leading carcinoma type in morbidity and mortality, distinguished by one of the lowest five-year survival rates.Despite improvements with incorporation of immune checkpoint therapy in certain contexts, systemic immune-related adverse events and the immunosuppressive tumour microenvironment(TME) constrain their effectiveness.Consequently, cytokines have emerged as a next-generation immunotherapy that can convert immunologically 'cold' tumours into 'hot' ones. 1 Interleukin-12 (IL12), a potent cytokine, has demonstrated significant efficacy in stimulating interferon-γ (IFN-γ) production and enhancing the cytolytic activity of immune cells.However, current research on IL12 normally focuses on intratumour injection due to the off-target-induced toxicity in systemic delivery.2 Therefore, developing targeted and localised delivery platforms for IL12 is critical for deep-organ tumours, especially lung cancer.Our research introduces IL12 messenger RNA (mRNA)-loaded exosomes (IL12-Exo), which are directly delivered into the lung TME through inhalation, providing a groundbreaking approach to lung cancer immunotherapy.

Source: Clinical and Translational Medicine

DOI: 10.1002/ctm2.70186

Authors: Mengrui Liu, Brian Henick, Ke Cheng

Institutions: Herbert Irving Comprehensive Cancer Center, Columbia University

Language: English

Topic: Extracellular vesicles in disease

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,470